BREAKING🔔 The 21st paper from G2P-Japan🇯🇵 is out at Nature Communications @NatureComms . We illuminated the virological characteristics of SARS-CoV-2 XBB variant (aka #Gryphon), generated by the recombination of two #Omicron subvariants. Please RT! 1/ nature.com/articles/s4146…
In late 2022, the Omicron subvariants have highly diversified. An example is BQ.1.1, which have convergently acquired amino acid substitutions at five critical residues in the spike protein: R346T, K444T, L452R, N460K & F486V. We reported it as below⬇️ 2/
Another variant of concern is XBB. First, two young talents, @jampei2 & @SpyrosLytras, showed that XBB emerged by recombination of two co-circulating BA.2 lineages, BJ.1 & BM.1.1.1 (a progeny of BA.2.75), during summer 2022. 3/
We showed that the Re values of XBB lineages are comparable with or slightly higher than those of BQ.1 lineages, and notably, XBB and BQ.1 lineages are becoming dominants in Eastern and Western regions of the world, respectively. 4/
Neutralization assay revealed that XBB.1 is the most profoundly resistant variant to BA.2/5 breakthrough infection sera ever (!!). >30-fold more resistant to BA.2 breakthrough infection sera than BA.2, >13-fold more resistant to BA.5 breakthrough infection sera than BA.2... 5/
XBB.1 spike is more fusogenic than BA.2.75 spike. Notably, the recombination breakpoint is located in the receptor-binding domain of spike, and each region of recombined spike conferred both immune evasion and augmented fusogenicity to the XBB.1 spike. 6/
Finally, the intrinsic pathogenicity of XBB.1 in hamsters is comparable to or even lower than that of BA.2.75. 7/
Our multiscale investigation provided evidence suggesting that #XBB is the first documented example of a SARS-CoV-2 variant that increased its fitness (Re) through recombination rather than substitutions. 8/8
• • •
Missing some Tweet in this thread? You can try to
force a refresh
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Keiya @Keiya717, is out at @biorxivpreprint. We assessed the humoral immunity induced by JN.1 mRNA vaccines against a broad range of SARS-CoV-2 variants including JN.1, KP.3.1.1 & XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
In this study, we used 2 mRNA vaccines, one is from Pfizer/BioNTech🇺🇸🇩🇪, while another is from Daiichi-Sankyo🇯🇵. The good news is that there are no significant differences between them and both broadly neutralized a variety of SARS-CoV-2 including JN.1, KP.3.1.1 and XEC. 2/
But there are two scientific interests.
First, compared to our recent study using JN.1 and KP.3.3 breakthrough (i.e. natural) infection sera, antiviral humoral immunity against KP.3 and XEC was weakly induced. However, JN.1 mNRA vaccine can. Why🤔?? 3/
BREAKING🔔 A new study from G2P-Japan🇯🇵, led by Yu in my lab, is out at bioRxiv @biorxivpreprint. We elucidated the virological characteristics of SARS-CoV-2 #XEC. Please repost🔥 1/ biorxiv.org/content/10.110…
Compared with KP.3, #XEC harbors two spike substitutions, S:T22N and S:F59S. Recombination analysis by Shusuke @KawakuboShusuke showed that XEC is a recombinant lineage of KS.1.1 (JN.13.1.1.1) and KP.3.3 (JN.1.11.1.3.3) with a breakpoint at genomic position 21,738–22,599. 2/
Transmissibility/fitness (Re):
Molecular phylogenetic-epidemic dynamics modeling led by Jumpei @jampei2 and Kaho showed that the Re of #XEC is greater than that of KP.3.1.1, the most predominant variant in the world. 3/
BREAKING🔔 Here I want to quickly report our new results from G2P-Japan🇯🇵 before the preprint publication. We have elucidated the virological characteristics of SARS-CoV-2 KP.3.1.1 - a progeny of JN.1. Please RT🔥 1/
Cf.1 A new one, KP.2 (JN.1.11.1.2), has been already elucidated. 2/